• KOL
    • Arthritis
    • Arthritis Kols
    • Thierry E Appelboom

      Thierry E Appelboom

      Hopital Erasme Brussels, Belgium. | University of Brussels, Belgium | Hopital Erasme, Brussels, Belgium. | Department of Rheumatology, Erasme Hospital, University of Brussels, ...

       

       

      KOL Resume for Thierry E Appelboom

      Year
      2016

      Hopital Erasme Brussels, Belgium.

      2014

      University of Brussels, Belgium

      2013

      Hopital Erasme, Brussels, Belgium.

      2012

      Department of Rheumatology, Erasme Hospital, University of Brussels, 808 Route de Lennik, 1070, Brussels, Belgium

      2009

      Service de rhumatologie, hôpital Erasme, université Libre de Bruxelles, Bruxelles, Belgique

      2007

      Division of Rheumatology and Physical Medicine, Hôpital Erasme, Université libre de Bruxelles, Brussels, Belgium

      2006

      Division of Rheumatology and Physical Medicine, Hôpital Erasme, Université libre de Bruxelles, 808, Route de Lennik, 1070, Brussels, Belgium

      2005

      Erasmus Hospital, University of Brussels, Belgium.

      Erasme University Hospital, B 1070 Brussels, Belgium

      2003

      2002

      Erasmus University Hospital, University of Brussels, 808 route de Lennik, B-1070 Brussels, Belgium.

      Division of Rheumatology, Université Libre de Bruxelles – Hôpital Erasme, Brussels, Belgium, Belgium

      Erasme University Hospital

      2001

      Department of Rheumatology, Erasmus University Hospital of Brussels, Belgium.

      2000

      Division of Rheumatology, Erasme University Hospital, Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium

      1999

      Hôpital Erasme, Department of Rheumatology, Université Libre de Bruxelles, 808 route de Lennik, B-1070, Brussels, Belgium

      1998

      Hopital Erasme; Brussels, Belgium

      1997

      From the Dept of Rheumatology, Erasmus Hospital, Free University of Brussels, Belgium

      1996

      From the Division of Rheumatology, Erasmus University Hospital, University of Brussels, Belgium

      1995

      Chief Division of Rheumatology, Erasmus University Hospital, University of Brussels, Brussels, Belgium

      1994

      Sleep Laboratory, Department of Psychiatry, Rheumatology Unit, Psychiatric Consultant, Erasme Hospital, Serolab, Lausanne, Switzerland;, IRIBHN, Brussels Free University, Brussels, Belgium

      Division of Rheumatology, Erasmus Hospital, 808, route de Lennik, B-1070, Brussels

      1993

      Division of Rheumatology, Erasmus Hospital, University of Brussels, Brussels, Belgium

      1992

      Service de Rhumatologie, Hǒpital Erasme, School of Medicine, University of Brussels, Belgium

      1991

      Unit of Magnetic Resonance, School of Medicine, University of Brussels, Brussels, Belgium

      1990

      Division of Rheumatology, Erasmus Hospital, University of Brussels

      1989

      Division of Rheumatology, Erasmus University Hospital, University of Brussels, Belgium

      1988

      Division of Rheumatology, Erasmus University Hospital and Center for the Preservation and the Study of Medical Heritage, University of Brussels, Brussels, Belgium

      1987

      Erasmus University Hospital—University of Brussels 808, Route de Lennik B-1070, Brussels, Belgium

      1986

      USA

      1984

      Division of Rheumatology, Erasme University Hospital, Brussels, Belgium, and Metropolitan General Hospital, San Antonio, Tex., USA

      Department of Immunology and Hematology, Erasme Hospital, Universite Libre de Bruxelles, 1070, Brussels, Belgium

      1983

      Service et Laboratoire de Rhumatologie, Hôpital Erasme, Université Libre de Bruxelles, 808 Route de Lennik, B-1070, Bruxelles, Belgium

      1981

      Fondation Robert Debré, Brussels, Belgium

      1980

      Cliniques Universitaires de Bruxelles, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles Belgium

      1979

      Departments of Immunology and Rheumatology, Saint-Pierre University Hospital, Brussels, Belgium

      1978

      Departments of Rheumatology and Immunology, Hôpital Universitaire Saint-Pierre, UniversitéLibre de Bruxelles, 1000 Brussels, Belgium

       

       

      Thierry E Appelboom: Influence Statistics

      Sample of concepts for which Thierry E Appelboom is among the top experts in the world.
      Concept World rank
      treatment comorbidity polymedication #1
      lifes broad range #1
      fresh serum variations #1
      belgian curcumin #1
      c5a activation products #1
      acquired 16th #1
      century arthritis #1
      om8980 #1
      presented features sle #1
      mononuclear cells hagg #1
      publication arthritis acquired #1
      flexofytol painful osteoarthritis #1
      flexofytol older #1
      serumtreated zymosan serum #1
      painful hip radiological #1
      il1 activity measurable #1
      medullary impairment #1
      radiological modification #1
      patients flexofytol #1
      osteonecrosis biopsy #1
      kda hagg #1
      sister catherine #1
      fibroblastic tissue evidence #1
      formal written accounts #1
      rheumatologists publication #1
      hagg mononuclear cells #1
      children rnp #1
      neck diffuse low #1
      zymosan smaller quantities #1
      activation products pmn #1
      effects flexofytol #1
      signal core biopsy #1
      century steroidal #1
      polymorphonuclear cell adherence #1
      hagg stimulation fluorography #1
      idiopathic osteonecrosis core #1
      trabecular bone necrosis #1
      comorbidity polymedication #1
      difference raynaud phenomenon #1
      ancient numerous examples #1
      flexofytol quality life #1
      acquired 16th century #1
      immunoglobulins mononuclear #1

       

      Prominent publications by Thierry E Appelboom

      KOL-Index: 11118

      OBJECTIVE: T cells are involved in the pathogenesis of rheumatoid arthritis (RA). In animal models of autoimmune diseases, blockade of costimulatory molecules on antigen-presenting cells has been demonstrated to be effective in preventing or treating this disease by preventing T cell activation. To date, the effect of costimulatory blockade in patients with RA is unknown. The goal of this multicenter, multinational study was to determine the safety and preliminary efficacy of ...

      Known for Costimulatory Blockade | Rheumatoid Arthritis | Autoimmune Diseases | Cell Activation | Animal Models
      KOL-Index: 11061

      OBJECTIVE: To study the relationship of spinal inflammation and fatty degeneration (FD) as detected by MRI and new bone formation seen on conventional radiographs (CRs) in ankylosing spondylitis (AS).

      METHODS: CRs at baseline, 2 years and 5 years and spinal MRIs at baseline and 2 years of 73 AS patients treated with infliximab in European AS Infliximab Cohort were available. Relative risks (RR) were calculated with a general linear model after adjustment for within-patient ...

      Known for New Bone Formation | 2 Years | Ankylosing Spondylitis | Inflammation Baseline | Spinal Lesions
      KOL-Index: 9335

      Abstract. Although fluoride salts have been shown to be capable of linearly increasing spinal bone mineral density (BMD) in postmenopausal osteoporosis, the effects of this gain in density on the vertebral fracture rate remain controversial. We conducted a 2-year multicenter, prospective, randomized, double-masked clinical trial in 354 osteoporotic women with vertebral fractures (mean age 65.7 years). They received either fluoride (208 patients), given as sodium fluoride (50 mg/day) or ...

      Known for Postmenopausal Osteoporosis | Vertebral Fractures | Fluoride Salts | 2 Years | Density Calcium
      KOL-Index: 7546

      Mycophenolate mofetil (MMF) is a new immunosuppressive agent currently used in organ transplantation and under evaluation in immune-mediated inflammatory disorders such as rheumatoid arthritis. Although MMF was shown to inhibit purine nucleotide synthesis in lymphocytes, it is still unclear whether it might also exert direct antiinflammatory actions in vivo. To address this question, we evaluated the effects of MMF administration on the responses of mice to a single challenge with ...

      Known for Mycophenolate Mofetil | Murine Endotoxemia | Antiinflammatory Properties | Inbred Balb Mice | Nitric Oxide
      KOL-Index: 7302

      OBJECTIVES: We compare the symptomatic effects of 300 or 600mg daily of ASU in patients with knee osteoarthritis.

      METHODS: A multicenter, double blind, study comparing a daily intake of 300mg or 600mg of ASU and placebo. The study lasted 3 months and involved patients of both genders, aged 45 to 80 years and presenting with femoro-tibial knee osteoarthritis. The primary endpoint was NSAIDs and analgesics intake between D30 and D90.

      RESULTS: All efficacy parameters were significantly ...

      Known for Asu Placebo | Knee Osteoarthritis | Daily Intake | Soybean Unsaponifiables | Symptomatic Effects
      KOL-Index: 6737

      Various proteases are expressed in the minor salivary glands (MSG) of patients with Sjögren's syndrome (SS), and as we have already shown, prolactin is neosynthesized in the acinar cells of patients with SS. The present study aims to characterize the influence of PRL on the expression of cathepsin B and D in the MSG of patients with SS. Cathepsin B and D expression was investigated immunohistochemically in MSG of 30 patients with SS and 15 healthy volunteers. The presence of cathepsin B ...

      Known for Salivary Glands | Expression Cathepsin | Sjögrens Syndrome | Prolactin Prl | Patients Sjögren
      KOL-Index: 6535

      OBJECTIVE: Tumor necrosis factor alpha (TNFalpha) is a proinflammatory cytokine involved in the pathogenesis of Sjögren's syndrome (SS), and blockade of TNFalpha may reduce the activity of the disease. The purpose of this study was to evaluate the safety and potential efficacy of infliximab, a chimeric human-mouse anti-TNFalpha monoclonal antibody, in patients with active primary SS.

      METHODS: This was a single-center, open-label pilot study. Sixteen patients with active primary SS ...

      Known for Infliximab Patients | Primary Sjögren | Salivary Flow | Clinical Benefit | Dry Eyes
      KOL-Index: 6084

      In this randomized, double-blind, double-dummy trial, 113 patients with acute sciatica were treated with a single 15-mg dose of meloxicam given intramuscularly (n = 54) or orally (n = 59). There was a significant improvement in induced pain (as measured by using the straight-leg-raising test) in both treatment groups at 60 minutes (P < 0.005), and there was a significant difference in favor of the intramuscular formulation in terms of the time to maximum improvement of induced pain (P = ...

      Known for Acute Sciatica | Oral Meloxicam | Intramuscular Formulation | Local Tolerability | 30 Minutes

      Key People For Rheumatoid Arthritis

      Top KOLs in the world
      #1
      Paul Emery
      rheumatoid arthritis ankylosing spondylitis radiographic progression
      #2
      Josef Sebastian Smolen
      rheumatoid arthritis systemic lupus erythematosus radiographic progression
      #3
      James F Fries
      rheumatoid arthritis physical function systemic lupus erythematosus
      #4
      John Turner Sharp
      rheumatoid arthritis radiographic progression joint space width
      #5
      Frederick J Wolfe
      rheumatoid arthritis work disability rheumatic diseases
      #6
      Matthew H Liang
      rheumatoid arthritis systemic lupus erythematosus lyme disease

      Thierry E Appelboom:Expert Impact

      Concepts for whichThierry E Appelboomhas direct influence:Rheumatoid arthritis,  Femoral head,  Salivary glands,  Hyaluronic acid,  Ankylosing spondylitis,  Infliximab patients,  Magnetic resonance,  Postmenopausal osteoporosis.

      Thierry E Appelboom:KOL impact

      Concepts related to the work of other authors for whichfor which Thierry E Appelboom has influence:Rheumatoid arthritis,  Femoral head,  Ankylosing spondylitis,  Bone marrow,  Inosine pranobex,  Autoimmune diseases,  Sjögren syndrome.


       

      Tools

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile


      Hopital Erasme Brussels, Belgium. | University of Brussels, Belgium | Hopital Erasme, Brussels, Belgium. | Department of Rheumatology, Erasme Hospital, University of Brussels, 808 Route de Lennik, 1070, Brussels, Belgium | Service de rhumatologie, hô

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.